• SU 5402: Reliable Cell Assay Workflows

  2026-08-20

  This scenario-driven guide explains how SU 5402, SKU A3843, can support mechanistic and reproducible cell viability, proliferation, cytotoxicity, and signaling studies. It covers dose selection, DMSO handling, orthogonal validation, interpretation, and practical product-selection criteria.

• AMPK–JAK2/STAT3 Signaling in Obesity-Related Asthma

  2026-08-20

  Lei and colleagues identify reduced AMPK signaling and M1 macrophage polarization as linked features of obesity-related asthma, with evidence that AMPK activation attenuates airway inflammation through the JAK2/STAT3 pathway. The study integrates mouse and RAW264.7-cell models with histology, molecular assays, immunostaining, and cytokine profiling, providing a mechanistic framework for evaluating macrophage-centered interventions.

• BACE Inhibition and Synaptic Transmission in Alzheimer’s

  2026-08-19

  Satir et al. examined whether partial β-secretase inhibition can lower amyloid β secretion without disrupting neuronal communication. Using primary rat cortical cultures and optical electrophysiology, the study identified a functional distinction between moderate Aβ reduction and stronger inhibition that impaired synaptic transmission, offering a useful framework for interpreting exposure and safety in Alzheimer’s disease research.

• TDRD9 siRNA Nanoparticles in P. aeruginosa Lung Injury

  2026-08-19

  This study identifies TDRD9 as a regulator of neutrophil cuproptosis during Pseudomonas aeruginosa lung infection and develops hyaluronic acid-coated peptide nanoparticles for siRNA delivery. Across human samples, mouse models, and human lung organoids, TDRD9 silencing reduced neutrophil accumulation, pulmonary inflammation, and tissue injury while improving infection-related outcomes.

• Puromycin Aminonucleoside: From Injury to Insight

  2026-08-18

  Puromycin aminonucleoside is more than a nephrotoxic reagent: it is a controlled perturbation for connecting podocyte architecture, glomerular filtration failure, and proteome-level stress responses. This thought-leadership perspective outlines how to use the aminonucleoside moiety of puromycin strategically in renal disease models while applying emerging solubility-aware proteomics with appropriate translational caution.

• In Vitro Antibacterial Activity of Leucomycin

  2026-08-18

  Iwata and Akiba provided one of the early systematic evaluations of Leucomycin, including its A1 fraction, against clinically relevant bacteria and antibiotic-resistant staphylococci. Their comparative agar, broth, and paper-disc experiments established a broad phenotypic spectrum and created a useful foundation for later macrolide resistance characterization and antibacterial drug discovery.

• Biotin-HPDP for Reliable Thiol Labeling

  2026-08-17

  Learn how Biotin-HPDP (SKU A8008) supports reversible thiol-specific protein labeling, streptavidin-based detection, and orthogonal interpretation of viability or cytotoxicity experiments. This scenario-driven guide covers compatibility, optimization, controls, and practical product-selection criteria.

• ECL Western Blotting Substrate: Practical Guide

  2026-08-17

  ECL Western Blotting Substrate (SKU K2187) is a luminol-based, nonradioactive horseradish peroxidase detection reagent for chemiluminescent immunoblots. It is intended for HRP Western blot workflows using X-ray film or CCD imaging, not for fluorescent or radioisotopic detection, and the prepared solution should be used promptly.

• PR-619: Turning DUB Biology into Translational Insight

  2026-08-16

  PR-619 offers a reversible, broad-spectrum way to perturb deubiquitylating enzymes without directly inhibiting proteasomal catalytic activity. This thought-leadership guide connects mechanism, assay design, physicochemical control, and translational decision-making across cancer biology research, autophagy, and neurodegenerative disease models.

• Lactylation, NSUN2, and Neural Invasion in PDAC

  2026-08-15

  This 2026 Theranostics study identifies NSUN2 K692 lactylation as a metabolic link between lactate accumulation and perineural invasion in pancreatic ductal adenocarcinoma. Integrated clinical, cellular, transcriptomic, and animal-model experiments support a lactate–NSUN2–m5C–CDCP1/STC1 pathway that stabilizes pro-invasive transcripts and may provide mechanistically informed targets for limiting neural spread.

• Separating Growth Arrest from Cell Death in Drug Response

  2026-08-14

  Hannah Schwartz’s dissertation identifies a central interpretive problem in cancer pharmacology: relative viability and fractional viability are often treated as interchangeable even though they capture different biological outcomes. Its framework shows that drug-induced proliferation arrest and cell death can occur in different proportions and on different timelines, supporting more precise evaluation of anticancer responses in vitro.

• SU 5402: Reliable RTK Assay Design

  2026-08-14

  This scenario-based guide explains how SU 5402 (SKU A3843) can clarify receptor tyrosine kinase biology in viability, proliferation, cell-cycle, and apoptosis experiments. It covers stock preparation, assay controls, mechanistic interpretation, and practical vendor-selection criteria without treating biochemical potency as a universal cellular dose.

• Caspase-4 Colorimetric Assay Kit Workflow

  2026-08-13

  Turn pyroptosis and inflammatory signaling questions into a practical, quantitative workflow with LEVD-pNA cleavage and pNA calibration. This guide shows how to distinguish caspase-4 enzyme activity from broader cell-death phenotypes and how to extend the assay to ER-targeted cancer research.

• 2X HyperFusion High-Fidelity Master Mix Guide

  2026-08-13

  2X HyperFusion High-Fidelity Master Mix combines a fusion proofreading polymerase with optimized buffer and dNTP components for high accuracy DNA amplification. Its reported blunt-end product generation, fragment capability up to 10 kb, and rapid extension guidance make it relevant to cloning PCR applications, while the cited cancer-immunotherapy study provides application context rather than direct validation of this reagent.

• Mitocytosis-Targeted Mitochondrial Therapy

  2026-08-12

  Deng and colleagues show that mitocytosis can blunt mitochondria-targeted antimetastatic therapy in migrasome-rich breast tumors. Their hybrid membrane nanoplatform combines mitochondrial damage with integrin-mediated mitocytosis inhibition, providing a mechanistic strategy to improve treatment response in the 4T1 model.

15405 records 1/1027 page Next 12345 下5页 Last page